Study of Sputnik Light in the elderly in Argentina has shown efficacy of up to 83.7% of the vaccine
A study on the effectiveness of the Russian Sputnik Light coronavirus vaccine among elderly people in Argentina has been published in the peer-reviewed medical journal EClinicalMedicine published by the leading medical journal The Lancet, the Russian Direct Investment Fund (RDIF) said.
“The Russian Direct Investment Fund (RDIF, a sovereign fund of the Russian Federation) announces the publication in the international peer-reviewed journal EClinicalMedicine (published by the leading medical journal The Lancet) of a study on the effectiveness of the Sputnik Light coronavirus vaccine (first component of Sputnik V vaccine) in vaccinating older people in Buenos Aires Province, Argentina”, – the statement said.
The foundation added that according to a study in the province of Buenos Aires, Sputnik Lite showed an efficacy of 78.6-83.7% against coronavirus among older people aged 60-79, who are at higher risk.
The authors of the published study, according to the report, were 15 specialists from the Buenos Aires Province Ministry of Health, as well as the Faculty of Medical Sciences at National University of La Plata, the Department of Immunology at Sister Maria Ludovica Children’s Hospital (La Plata, Buenos Aires Province) and the Computing Institute at the University of Buenos Aires.
“Sputnik Lite”, as noted by the RFPI, has also demonstrated an effectiveness against hospitalisation of 82.1-87.6%, according to calculations based on data from more than 40,000 people obtained by the Buenos Aires Province Ministry of Health.